It's a choice to move forward: women's perceptions about treatment decision making in recurrent ovarian cancer

被引:25
作者
Elit, L. [1 ,2 ]
Charles, C. [3 ]
Dimitry, S. [1 ]
Tedford-Gold, S. [4 ]
Gafni, A. [3 ,5 ]
Gold, I. [4 ,6 ]
Whelan, T. [1 ,3 ]
机构
[1] Juravinski Canc Ctr, Support Canc Care Unit, Hamilton, ON L8V 5C2, Canada
[2] McMaster Univ, Dept Obstet & Gynecol, Hamilton, ON, Canada
[3] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada
[4] Core Res & Consulting, Ottawa, ON, Canada
[5] McMaster Univ, Ctr Hlth Econ & Policy Anal, Hamilton, ON, Canada
[6] Assoc Fac Med Canada, Ottawa, ON, Canada
关键词
cancer; oncology; treatment decision making; recurrent ovarian cancer; qualitative research; PREFERENCES; INSTRUMENT; ENCOUNTER; THERAPY;
D O I
10.1002/pon.1562
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: This research explores the treatment decision-making (TDM) experiences of women with recurrent ovarian cancer (ROC) with regard to treatment options; their understanding of risks and benefits of various treatment options; the decision-making role they want for themselves and for their oncologist; and the social context of the consultation as it pertains to the decision. Methods: We conducted semi-structured interviews with 26 women at the time of first recurrence. Through inductive data analysis key themes were identified. Results: Many women describe self-identifying the cancer recurrence fairly quickly due to new symptoms. Many feel that the goal for treating their recurrence is to control versus cure the cancer. They describe the subsequent process of diagnosis and TDM for ROC as quick and straightforward with all women accepting the oncologists' treatment recommendation. They feel that the type and number of treatment options are limited. They have a strong desire for physician continuity in their care. Participants feel that their doctor's recommendations as well as their previous experience with ovarian cancer are strong factors influencing their current TDM process. Conclusions: Shared decision making is based on a simultaneous participation of both the physician and patient in TDM. When faced with ROC, women feel that their doctor's recommendation and their past experience with treatment and TDM are prominent factors influencing the current TDM process. Copyright (C) 2009 John Wiley & Sons, Ltd.
引用
收藏
页码:318 / 325
页数:8
相关论文
共 19 条
[1]   Shared decision-making in the medical encounter: What does it mean? (Or it takes at least two to tango) [J].
Charles, C ;
Gafni, A ;
Whelan, T .
SOCIAL SCIENCE & MEDICINE, 1997, 44 (05) :681-692
[2]   Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model [J].
Charles, C ;
Gafni, A ;
Whelan, T .
SOCIAL SCIENCE & MEDICINE, 1999, 49 (05) :651-661
[3]  
CHARLES C, 1998, WORKING PAPER SERIES
[4]  
CHARLES C, 1996, TEACHING MED S UNPUB
[5]   Treatment preferences in recurrent ovarian cancer [J].
Donovan, KA ;
Greene, PG ;
Shuster, JL ;
Partridge, EE ;
Tucker, DC .
GYNECOLOGIC ONCOLOGY, 2002, 86 (02) :200-211
[6]   Use of systemic therapy in women with recurrent ovarian cancer - Development of a national clinical practice guideline [J].
Elit, L. ;
Zitzelsberger, L. ;
Fung-Kee-Fung, M. ;
Brouwers, M. ;
Graham, I. D. ;
Browman, G. ;
Hoskins, P. ;
Lau, S. ;
Ghatage, P. .
GYNECOLOGIC ONCOLOGY, 2007, 106 (01) :181-192
[7]   Women's perceptions about treatment decision making for ovarian cancer [J].
Elit, L ;
Charles, C ;
Gold, I ;
Gafni, A ;
Farrell, S ;
Tedford, S ;
Dal Bello, D ;
Whelan, T .
GYNECOLOGIC ONCOLOGY, 2003, 88 (02) :89-95
[8]   Patients' preferences for therapy in advanced epithelial ovarian cancer: Development, testing, and application of a bedside decision instrument [J].
Elit, LM ;
Levine, MN ;
Gafni, A ;
Whelan, TJ ;
Doig, G ;
Streiner, DL ;
Rosen, B .
GYNECOLOGIC ONCOLOGY, 1996, 62 (03) :329-335
[9]  
Finn M, 2000, THESIS BROCK U ST CA
[10]  
Fung-Kee-Fung M, 2007, Curr Oncol, V14, P195